natgillin/translations-raw huggingface dataset:
Injection site reaction-related adverse events were less frequent in inadequately controlled patients compared to medically naïve patients.
Pri bolnikih, pri katerih bolezen ni bila ustrezno urejena, so bili neželeni učinki, povezani z reakcijo na mestu injiciranja, manj pogosti kot pri bolnikih, ki predhodno še niso bili zdravljeni.
Injection site reaction2
reakcija na mestu injiciranja2
Injection site reactions
reakcije na mestu
Injection site reactions
Reakcije na vbodnem mestu
Injection site reactions
SPREMEMBE NA MESTU
Injection site reactions
Spremembe na mestu injiciranja
Injection site reactions (including injection site erythema, discolouration, pain, pruritus, macule, swelling, bruising, hypertrophy, induration, reaction, atrophy, nodule, rash, papule, haematoma, inflammation, urticarial, warmth, haemorrhage, cellulitis and mass) are the most common adverse reactions observed in about 73% of the patients in clinical studies.
Reakcije na mestu injiciranja (vključno z eritemom, obarvanjem, bolečino, pruritusom, makulo, oteklino, modrico, hipertrofijo, zatrdlino, reakcijo, atrofijo, vozličem, izpuščajem, papulo, hematomom, vnetjem, koprivnico, toploto, krvavitvijo, celulitisom in tvorbo na mestu injiciranja) so najpogostejši neželeni učinki, ki so jih v kliničnih študijah opazili pri približno 73 % bolnikov.
Injection site reactions (including injection site haematoma, pain, haemmorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) have been reported in 2.6% of patients treated with Xultophy.
O reakcijah na mestu injiciranja (vključno s hematomom, bolečino, krvavitvijo, rdečino, vozliči, otekanjem, spremembo barve, pruritusom, toplino in zatrdlino na mestu injiciranja) so poročali pri 2,6 % bolnikov, zdravljenih z zdravilom Xultophy.
injection site reactions (including pain, swelling, redness or itching)
reakcije na mestu injiciranja (vključno z bolečino, oteklostjo, pordelostjo in srbenjem)
injection site reactions (including pain, swelling, redness or itching);
reakcije na mestu injiciranja (vključno z bolečino, oteklostjo, pordelostjo in srbenjem);
injection site reactions (including pain, swelling, redness or itching;
reakcije na mestu injiciranja (vključno z bolečino, oteklostjo, pordelostjo in srbenjem);
Injection site reactions (including redness, hardness, pain, bruising, itching, tingling and irritation)
reakcije na mestu injiciranja (vključno s pordelostjo, zatrdlino, bolečino, podplutbo, srbenjem, mravljinci in draženjem),
injection site reactions (including: redness, discomfort, itching, local pain or stinging, and an itchy rash) low TSH hypersensitivity (allergic reactions), these reactions include hives (urticaria), itching, flushing, difficulty in breathing and rash.
reakcije na mestu injiciranja (vključujejo: pordelost, neugodje, srbenje, lokalno bolečino ali zbadanje in srbeči izpuščaj) nizka raven TSH preobčutljivost (alergijske reakcije); te reakcije vključujejo koprivnico (urtikarijo), srbenje (pruritis), vročinske oblive, težave z dihanjem in izpuščaj.
Injection site reactions (infusion/injection site bruising, pain, reaction, swelling, warmth, haemorrhage, irritation, rash)
reakcije na mestu injiciranja (modrica na mestu infundiranja/injicira nja, bolečina, reakcija, oteklina, občutek toplote, krvavitev, draženje, izpuščaj)
Injection site reactions (Injection site discomfort, Injection site pain, Puncture site reaction)
reakcije na mestu injiciranja (nelagodje na mestu injiciranja, bolečine na mestu injiciranja, reakcije na mestu vboda)
injection site reactions (redness)
reakcije na mestu injiciranja (rdečina)
Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with insulin.
Med zdravljenjem z insulinom se lahko pojavijo reakcije na injekcijskem mestu (pordelost, oteklost, srbenje, bolecine in hematomi na injekcijskem mestu).
Injection site reactions (such as hardening and pain)
reakcije na mestu injiciranja (kot so zatrdlina in bolečina)
Injection site reactions (such as inflammation, mass, ecchymosis)
reakcije na mestu injiciranja (na primer vnetje, masa, ekhimoze)
Injection site reactions and other post-immunisation effects are relatively mild and adequately described in the SPC.
Reakcije na mestu injiciranja in drugi učinki po cepljenju so sorazmerno blagi in so primerno opisani v povzetku glavnih značilnosti zdravila.
Injection site reactions e
Reakcije na mestu injiciranjae
Injection site reactions generally did not necessitate discontinuation of the medicinal product.
Pojav reakcije na mestu injiciranja običajno ne narekuje ukinitve zdravljenja.
Injection site reactions have been reported in approximately 2% of patients receiving Victoza in long­ term (26 weeks or longer) controlled trials.
Reakcije na mestu injiciranja so se pojavile pri približno 2 % bolnikov, ki so prejemali zdravilo Victoza v dolgotrajnih kontroliranih preskušanjih (26 tednov ali dlje).
Injection site reactions include effects like pain, urticaria at injection site, haematoma and erythema.
Reakcije na mestu injiciranja so vključevale učinke, kot so bolečina, urtikarija na mestu injiciranja, hematom in eritem.
Injection site reactions include redness, pain, itching, hives, swelling, or inflammation.
Med reakcijami na mestu injiciranja so pordelost, bolečine, srbenje, urtikarija, otekanje ali vnetje.
Injection site reactions include redness, pain, itching, hives, swelling, or inflammation.
Reakcije na mestu injiciranja so pordelost, bolečine, srbenje, urtikarija, otekanje ali vnetje.
Injection site reactions include redness, pain, itching, hives, swelling, or inflammation.
Reakcije na mestu injiciranjaMed takšnimi reakcijami so pordelost, bolečine, srbenje, urtikarija, otekanje ali vnetje.
Injection site reactions including pain, redness, swelling; fatigue
reakcije na mestu injiciranja, vključno z bolečino, rdečino in oteklino; utrujenost
Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common.
Reakcije na mestu injiciranja, vključno z rdečico, oteklino, obarvanostjo kože, vnetjem, bolečino in razpokanjem kože, so zelo pogoste.
Injection site reactions like injection site haematoma, haemorrhage and nodule
reakcije na mestu injiciranja, kot so hematom, krvavitev in vozlič
Injection site reactions like injection site induration, fever >39°C rectally (age < 2 years)
reakcije na mestu injiciranja, kot je induracija na mestu injiciranja, zvišana telesna temperatura > 39 °C rektalno (starost < 2 leti)
Injection site reactions like thinning of skin tissue, a copious discharge of blood from the blood vessels, thickening
reakcije na mestu injiciranja kot je tanjšanje kožnega tkiva, obilno izločanje krvi iz žil, odebelitev
injection site reactions nausea
reakcije na mestu injiciranja slabost
Injection site reactions occurred in 21% of SBS patients treated with Revestive.
Reakcije na vbodnem mestu so se pojavile pri 21 % bolnikov s SKČ, zdravljenih z zdravilom Revestive.
Injection site reactions such as swelling, erythema, pain, pruritus
reakcije na mestu injiciranja, na primer oteklina, eritem, bolečina, pruritus
Injection site reactions were observed more frequently in prolonged-release exenatide treated patients versus comparator-treated patients (16 % versus range of 2-7 %) during the 6-month controlled phase of studies.
V 6-mesečni kontrolirani fazi študij so ugotovili, da so bile reakcije na mestu injiciranja pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, bolj pogoste kot pri zdravljenju s podobnimi zdravili (16 % proti 2-7 %).
Injection site reactions were reported in 13.6% of patients enrolled in the phase III study in Cushing’s disease.
O reakcijah na mestu injiciranja so poročali pri 13,6 % bolnikov, ki so bili vključeni v študijo faze III pri bolnikih s Cushingovo boleznijo.
Injection site reactions*
reakcije na mestu injiciranja
Injection site reactions**
reakcije na mestu injiciranja
Injection site reactions***
reakcije na mestu injiciranja
Injection site reactions, Asthenia
reakcije na mestu injiciranja, astenija
Injection site reactions, including erythema, bruising, pruritus, swelling, inflammation, pain, dermatitis, oedema, urticaria, vesicles
reakcije na mestu injiciranja, vključno z eritemom, podplutbami, pruritusom, oteklino, vnetjem, bolečino, dermatitisom, edemi, koprivnico, mehurčki
Injection site reactions, including injection site erythaema (uncommon (≥ 1/1000 to < 1/100)) as well as injection site pain (common events ≥ 1/100 to < 1/10) have occurred on initial or subsequent treatment with Neulasta.
Med začetnim ali nadaljnjim zdravljenjem z zdravilom Neulasta so se pojavile reakcije na mestu injiciranja, vključno z eritemom na mestu injiciranja (občasno (≥ 1/1.000 do < 1/100) kot tudi bolečino na mestu injiciranja (pogosti dogodki ≥ 1/100 do < 1/10).
Injection site reactions, redness, bruising or pain
Reakcije na mestu injiciranja, pordelost, podplutba ali bolečina
Injection site reactions, such as pain and/or inflammation
reakcije na mestu injiciranja, npr. bolečine in/ali vnetje
Injection site reactions, weakness (asthenia)
reakcije na mestu injiciranja, oslabelost (astenija)
Injection site reactions1
reakcije na mestu injiciranja1
Injection site reactions1 Pyrexia
reakcije na mestu injiciranja1 pireksija
Injection site reactions: injection site irritation, injection site pain, redness of the skin at injection site (injection / application site erythema)
reakcije na mestu injiciranja: draženje na mestu injiciranja, bolečina na mestu injiciranja, pordelost kože na mestu injiciranja (eritem na mestu injiciranja/aplikacije);
injection site reactions;
reakcije na mestu injiciranja,
Injection site redness
rdečina na mestu injiciranja
Injection site redness, injection site swelling
Začervenanie miesta vpichu
injection site sterile abscess
terilni abces na mestu injiciranja
Injection site swelling
otekanje na mestu injiciranja
Injection site swelling
oteklina na mestu injiciranja
injection site swelling, node and hardness
oteklina, vozlič in zatrdlina na mestu injekcije
Injection site swellings may result in mild to moderate pain in some animals in the initial days following injection.
Otekline na mestu injiciranja se lahko pri nekaterih živalih v začetnih dneh po injiciranju pokažejo kot blago do srednje boleče.
Injection site tenderness
občutljivost na mestu injiciranja
injection site thrombosis, infusion site inflammation, injection site pain, peripheral oedema
tromboza na mestu injiciranja, vnetje na mestu infundiranja,
injection site thrombosis, infusion site inflammation, injection site pain, peripheral oedema
tromboza na mestu injiciranja, vnetje na mestu infundiranja, bolečina na mestu injiciranja, periferni edem
Injection site urticaria
urtikarija na mestu
Injection site urticaria
urtikarija na mestu injiciranja
Injection site urticaria (itchy rash)
Urtikarija na mestu injiciranja (srbeči izpuščaj)
Injection site warmth
vroč občutek na mestu injiciranja
Injection site(s)
Mesta aplikacije
Injection site-vesicles.
mehurčki na mestu injiciranja
Injection site: Erythema 1,2, Pain/tenderness1,2 , Pruritus1,2, Swelling1,2
na mestu injiciranja: eritem1,2, bolečina/občutljivost1,2, pruritus1,2, otekanje1,2
Injection sites
injekcijski mesti
Injection Sites
Mesta injiciranja
Injection sites should be at least 5 cm apart.
Mesta injiciranja morajo biti medsebojno oddaljena vsaj 5 cm.
Injection sites should be rotated.
Mesta injiciranja menjujte.
injection Solution for
raztopina za
injection Solution for
raztopina za injiciranje
injection Solution for injection Solution for injection Solution for
raztopina za injiciranje
injection Solution for injection Suspension for injection
raztopina za injiciranje
injection steps
tran stegna.
injection Suspension for
uspenzija za
Injection through the arterial line of the extracorporeal circuit
Injiciranje v arterijsko linijo v zunajtelesnem krvnem obtoku
Injection vial (glass)
injekcijska viala (steklena)
Injection vial (type I glass)
Stekleno vialo tipa I
Injection volume
Odmerek
Injection volume (mL)
Volumen injiciranja (ml)
Injection volume to deliver Xiapex 0.58 mg dose†
Volumen injekcije za aplikacijo odmerka zdravila Xiapex 0,58 mg
Injection with Eylea has a minor influence on the ability to drive and use machines due to possible temporary visual disturbances associated either with the injection or the eye examination.
Zaradi začasnih motenj vida, povezanih z injekcijo ali preiskavo oči, imajo injekcije zdravila Eylea blag vpliv na sposobnost vožnje in upravljanja s stroji.
Injection-site bruising.
modrica na mestu injiciranja
Injection-site cellulitis *
celulitis na mestu injiciranja
Injection-site induration
otrdlina na mestu injiciranja
Injection-site rash.
izpuščaj na mestu injiciranja
injection-site reaction ( pain, redness, swelling, itching, and burning sensation of the skin near where the injection was given)
reakcija na mestu injiciranja (bolečina, pordelost, oteklost, srbenje in pekoč občutek v predelu kože, kamor ste dobili injekcijo),
injection-site reaction such as irritation, itching, bruising or stiff arm sudden hearing loss
reakcija na mestu injiciranja, kot so draženje, srbenje, podplutba ali otrdelost roke. nenadna izguba sluha.
Injection-site reactions
Reakcije na mestu injiciranja
Injection-site redness; injection-site pain; injection-site swelling.
rdečina na mestu injiciranja, bolečina na mestu injiciranja, oteklina na mestu injiciranja
Injection/ infusion site reactions
reakcije na mestu injiciranj a/infundi ranja
injection/infusion
EU/1/10/631/001
injection/infusion
EU/1/10/631/005
injection/infusion
EU/1/10/631/009
injection/infusion
µg/0,2 ml)
injection/infusion
µg/0,5 ml)
injection:
injiciranju:
Injection: Depo-medroxyprogesterone acetate (DMPA)/Efavirenz (150 mg IM single dose DMPA)
(150 mg i.m. enkratni odmerek DMPA)
Injection: Depomedroxyprogesterone acetate (DMPA)/Efavirenz (150 mg IM single dose DMPA)
(150 mg i.m. enkratni odmerek DMPA)
Injections and finger extension procedures may be administered up to 3 times per cord at approximately 4-week intervals.
Postopek injiciranja in postopek iztegovanja prstov se sme ponoviti do trikrat na posamezni vozlič v približno 4-tedenskih intervalih.
Injections may be into a vein, muscles or under the skin, depending on the species and the condition being treated.
Injekcije se dajejo v veno, mišico ali pod kožo, odvisno od vrste živali in bolezni, ki se zdravi.
Injections of Abilify were also more effective than placebo in reducing the symptoms of agitation, and were of similar effectiveness to lorazepam.
Injiciranje zdravila Abilify je bilo pri zmanjševanju simptomov agitacije prav tako učinkovitejše od placeba in podobno učinkovito kot lorazepam.
Injections of PANDEMIC INFLUENZA VACCINE
Cepivo PANDEMIC INFLUENZA VACCINE
Injections should be given in areas where the patient will not be exposed to pressure e.g. not close to waistband or belt and not close to the ribs.
Injekcij ne smete dajati v predele, ki so izpostavljeni pritisku, na primer v bližini pasu ali reber.
Injuries
poškodbe
Injury
poškodba
Injury
poškodbe
Injury , poisoning and procedural complications
Poškodbe, zastrupitve in zapleti pri posegih
Injury ,poisoning and procedural complications
Poškodbe, zastrupitve in zapleti pri posegih
Injury and poisoning
Poškodbe in zastrupitve
Injury and poisoning
Poškodbe in zastrupitve in zapleti pri posegih
Injury and poisoning and procedural complications
Poškodbe in zastrupitve in zapleti pri posegih
Injury and poisoning, and procedural complications
Poškodbe in zastrupitve in zapleti pri posegih
injury or pain at the injection site
bolečina ali poškodba na mestu injiciranja,
injury or pain at the injection site
bolečina ali poškodba na mestu injiciranja;
Injury poisoning and procedural complications
Poškodbe in zastrupitve in zapleti pri posegih
Injury poisoning, and procedural complications Common: Post procedural pain, abrasion Uncommon: Blister, post procedural haemorrhage
Poškodbe zastrupitve in zapleti pri posegih Pogoste: Bolečina po posegu, abrazija Občasne: Mehurji, krvavitev po posegu
Injury to the liver (hepatic disorder) including abnormal liver test results.
poškodbe jeter (bolezni jeter), vključno z nenormalnimi rezultati jetrnih testov,
injury, face oedema, pain, taste perversion
poškodba zaradi obsevanja, edem obraza, bolečina, spremenjeno okušanje
Injury, injection site pain
injiciranja
Injury, injection site pain
poškodba, bolečina na mestu
Injury, injection site pain
poškodba, bolečina na mestu injiciranja
Injury, poisoning
Poškodbe in
Injury, poisoning and
Poškodbe in zastrupitve in zapleti pri posegih
Injury, poisoning and
Preiskave
Injury, poisoning and procedural
Poškodbe in zastrupitve in zapleti pri posegih
Injury, poisoning and procedural complaint
Poškodbe in zastrupitve in zapleti pri posegih
Injury, poisoning and procedural complication
Poškodbe in zastrupitve in zapleti pri posegih
Injury, poisoning and procedural complications
Poškodbe in zastrupitve
Injury, poisoning and procedural complications
Poškodbe in zastrupitve in
Injury, Poisoning and Procedural Complications
Poškodbe in zastrupitve in zapleti
Injury, poisoning and procedural complications
Poškodbe in zastrupitve in zapleti pri
Injury, poisoning and procedural complications
Poškodbe in zastrupitve ter postopkovni zapleti
Injury, poisoning and procedural complications
Poškodbe, zastrupitve in zapleti postopkov
Injury, poisoning and procedural complications
Poškodbe, zastrupitve ter zapleti postopkov
Injury, poisoning, and procedural
Poškodbe, zastrupitve in zapleti pri postopkih
Injury, poisoning, and procedural complications
Poškodbe in zastrupitve in zapleti pri posegih
Injury, poisoning, and procedural complications
Poškodbe, zastrupitve in zapleti pri posegih
Injury, poisoning, and procedural complications
Poškodbe, zastrupitve in zapleti pri postopkih
Injury, poisoning, and procedural complications Common: Post procedural pain, abrasion Uncommon: Blister, post procedural haemorrhage
Poškodbe zastrupitve in zapleti pri posegih Pogoste: Bolečina po posegu, abrazija Občasne: Mehurji, krvavitev po posegu
Inlyta 1 mg film-coated tablet
Inlyta 1 mg filmsko obložena tableta
Inlyta 1 mg film-coated tablets
Inlyta 1 mg filmsko obložene tablete
Inlyta 1 mg film-coated tablets axitinib
Inlyta 1 mg filmsko obložene tablete aksitinib
Inlyta 3 mg film-coated tablet
Inlyta 3 mg filmsko obložena tableta
Inlyta 3 mg film-coated tablets
Inlyta 3 mg filmsko obložene tablete
Inlyta 3 mg film-coated tablets axitinib
Inlyta 3 mg filmsko obložene tablete aksitinib
Inlyta 3 mg is available in bottles of 60 tablets and blister packs of 28 tablets and 56 tablets.
Zdravilo Inlyta 3 mg je na voljo v plastenkah s 60 tabletami in v pretisnih omotih z 28 in 56 tabletami.
Inlyta 5 mg film-coated tablet
Inlyta 5 mg filmsko obložena tableta
Inlyta 5 mg film-coated tablets
Inlyta 5 mg filmsko obložene tablete
Inlyta 5 mg film-coated tablets axitinib
Inlyta 5 mg filmsko obložene tablete aksitinib
Inlyta 5 mg is available in bottles of 60 tablets and blister packs of 28 tablets and 56 tablets.
Zdravilo Inlyta 5 mg je na voljo v plastenkah s 60 tabletami in v pretisnih omotih z 28 in 56 tabletami.
Inlyta 7 mg film-coated tablet
Inlyta 7 mg filmsko obložena tableta
Inlyta 7 mg film-coated tablets
Inlyta 7 mg filmsko obložene tablete
Inlyta 7 mg film-coated tablets axitinib
Inlyta 7 mg filmsko obložene tablete aksitinib
Inlyta 7 mg is available in bottles of 60 tablets and blister packs of 28 tablets and 56 tablets.
Zdravilo Inlyta 7 mg je na voljo v plastenkah s 60 tabletami in v pretisnih omotih z 28 in 56 tabletami.
Inlyta can cause thyroid gland problems.
Zdravilo Inlyta lahko povzroči motnje delovanja žleze ščitnice.
Inlyta contains lactose (milk sugar)
Zdravilo Inlyta vsebuje laktozo (mlečni sladkor)
Inlyta could harm an unborn baby or breast-fed baby.
Zdravilo Inlyta bi lahko škodovalo nerojenemu otroku ali dojenemu otroku.
Inlyta is a medicine containing the active substance axitinib.
Inlyta je zdravilo, ki vsebuje zdravilno učinkovino aksitinib.
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Zdravilo Inlyta je indicirano za zdravljenje napredovalega karcinoma ledvičnih celic (RCC - renal cell carcinoma) pri odraslih bolnikih, po tem ko predhodno zdravljenje s sunitinibom ali citokinom ni bilo uspešno.
Inlyta is used when treatment with Sutent (sunitinib) or ‘cytokines’ (other cancer medicines) has failed.
Zdravilo Inlyta se uporablja, kadar zdravljenje z zdravilom Sutent (sunitinib) ali s citokini (drugimi zdravili za zdravljenje raka) ni bilo uspešno.
Inlyta may increase the risk of developing a hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin).
Zdravilo Inlyta lahko poveča tveganje za predrtje želodca ali črevesa ali za nastanek fistule (nenormalen, cevi podoben prehod iz ene normalne telesne votline do druge telesne votline ali kože).
Inlyta may increase the risk of developing heart failure events.
Zdravilo Inlyta lahko poveča tveganje za razvoj srčnega popuščanja.
Inlyta may increase your chance of bleeding.
Zdravilo Inlyta poveča možnosti, da pri vas pride do krvavitev.
INNER CARTON BOX CONTAINING 56 (14 SACHETS OF 4) AMPOULES
NOTRANJA ŠKATLA, KI VSEBUJE 56 AMPUL (14 VREČIC S PO 4 AMPULAMI)
Inner Carton Box for 10 pre-filled syringes with needles
Notranja kartonska škatla za 10 napolnjenih injekcijskih brizg z iglami Notranja kartonska škatla za 10 napolnjenih injekcijskih brizg brez igel
Inner Carton Box for 10 pre-filled syringes without needles
Notranja kartonska škatla za 10 napolnjenih injekcijskih brizg z iglami Notranja kartonska škatla za 10 napolnjenih injekcijskih brizg brez igel
Inner carton box will not include “Blue Box”.
Notranja kartonska škatla ne vključuje podatke za tako imenovano »modro okence«.
INNER CARTON CONTAINING SINGLE 28 CAPSULE BOTTLES (MULTIPACK) WITHOUT BLUE BOX
NOTRANJA ŠKATLA Z ENO PLASTENKO Z 28 KAPSULAMI (VELIKO PAKIRANJE) BREZ "BLUE BOX" PODATKOV
INNER CARTON FOR BLISTER PACK; front and backside
NOTRANJA ŠKATLA ZA PRETISNI OMOT; spredaj in zadaj
INNER CARTON FOR MULTIPACK (100 units/mL pre-filled pen (FlexTouch))
NOTRANJA ŠKATLA SKUPNEGA PAKIRANJA (Napolnjen injekcijski peresnik 100 enot/ml (FlexTouch))
INNER CARTON MULTIPACK OF 3 X (4 SINGLE-DOSE PRE-FILLED PENS) – WITH NO BLUE BOX
NOTRANJA ŠKATLA SKUPNEGA PAKIRANJA PO 3 X (4 NAPOLNJENI INJEKCIJSKI PERESNIKI Z ENKRATNIM ODMERKOM) – BREZ MODREGA OKENCA
INNER CARTON OF BLISTER MULTIPACK (WITHOUT BLUE BOX)
VMESNA ŠKATLA SKUPNEGA PAKIRANJA (BREZ MODREGA OKENCA)
INNER CARTON OF BOTTLE MULTIPACK (WITHOUT BLUE BOX)
VMESNA ŠKATLA SKUPNEGA PAKIRANJA Z VSEBNIKI (BREZ MODREGA OKENCA)
INNER CARTON OF MULTIPACK (WITHOUT BLUE BOX)
NOTRANJA ŠKATLA Z VEČ PAKETI (BREZ MODREGA OKVIRJA)
Inner carton of multipack of 120 (3 packs of 40) 200 mg/50 mg film-coated tablets) – without blue box
Vmesna škatla v multipakiranju s 120 (3 pakiranja s 40) 200mg/50mg filmsko obloženimi tabletami – brez modrega okenca
Inner carton of multipack of 14 film-coated tablets – without blue box
Notranja škatla (večkratno pakiranje) s 14 filmsko obloženimi tabletami – brez modrega okenca
Inner carton of multipack of 14 film-coated tablets – without blue box
Notranja škatla (večkratno pakiranje) vsebuje 14 filmsko obloženih tablet –brez modrega okenca
INNER CARTON SLEEVE, 42, 60, 84, 90 or 120 CAPSULES
NOTRANJI KARTON, 42, 60 84, 90 ali 120 KAPSUL
INNER CARTON SLEEVE, 42, 60, 84, 90 or 120 TABLETS
NOTRANJI KARTON, 42, 60 84, 90 ali 120 TABLET
INNER CARTON – PART OF MULTIPACK – WITHOUT BLUE BOX
NOTRANJA ŠKATLA – DEL SKUPNEGA PAKIRANJA – BREZ MODREGA OKENCA
INNER CARTON, MULTIPACK OF 3 X (4 SINGLE-DOSE KITS) – WITH NO BLUE BOX
NOTRANJA ŠKATLA SKUPNEGA PAKIRANJA PO 3 x (4 enoodmerni seti) – brez modrega okenca
INNER LID OF UNIT PACK CARTON
NOTRANJI ZAVIHEK NA ŠKATLI POSAMIČNEGA PAKIRANJA
Inner Needle Cap
NE name preberete
Inner Needle Cap
Notranji pokrovček igle
Inner needle cap
papirna nalepka
Inner Needle Cap
Prelepka
Inner needle cap
Zaščitni pečat
Inner needle cap
Zunanji pokrovček igle